Similar 5‐year HCC occurrence in Tenofovir‐ and Entecavir‐treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort

Summary Background Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs)...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary Pharmacology & Therapeutics (Suppl) 2021-03, Vol.53 (5), p.616-629
Main Authors: Pol, Stanislas, Bonnet, Delphine, Payssan‐Sicart, Virginie, Pomes, Chloe, Bailly, François, Beaudoin, Marjolaine, Giboz, Dominique, Hartig‐Lavie, Kerstin, Maynard, Marianne, Boutoille, David, Cavellec, Morane, Hubert, Isabelle, Goepfert, Pierre, Lannes, Adrien, Lunel, Françoise, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Chibah, Aziza, Keser, Sylvie, Bonardi, Karim, Sogni, Philippe, Foucher, Juliette, Hiriart, Jean‐Baptiste, Irlès‐Depé, Marie, Si Ahmed, Si Nafa, Amara, Nisserine Ben, Oules, Valérie, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Luckina, Elena, Messaoudi, Nadia, Moussali, Joseph, De Dieuleveult, Barbara, Goin, Héloïse, Labarrière, Damien, Potier, Pascal, Grando‐Lemaire, Véronique, Nahon, Pierre, Brulé, Séverine, Brener, Audrey, Laligant, Anne, Rabot, Aline, Baumert, Thomas F., Dofföel, Michel, Mutter, Catherine, Simo‐Noumbissie, Pauline, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani‐Nani, Sarah, Bernard, Marie‐Albertine, Bismuth, Michael, Caillo, Ludovic, Faure, Stéphanie, Ripault, Marie Pierre, Bureau, Christophe, Peron, Jean Marie, Robic, Marie Angèle, Tarallo, Léa, Faure, Marine, Froissart, Bruno, Hilleret, Marie‐Noelle, Zarski, Jean‐Pierre, Goria, Odile, François, Muriel, Ouedraogo, Christian, Varault, Anne, Angoulevant, Bénédicte, Chevance, Azeline, Serfaty, Lawrence, Coilly, Audrey, Duclos Vallée, Jean‐Charles, Tateo, Mariagrazia, Bonny, Corinne, Brigitte, Chanteranne, Muti, Léon, Babouri, Abdenour, Filipe, Virginie, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Merbah, Soraya, Debette‐Gratien, Maryline, Jacques, Jérémie, Lassailly, Guillaume, Artu, Florent, Louvet, Alexandre, Bardou, Marc, Mouillot, Thomas, Bacq, Yannick, Barbereau, Didier, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Saillard, Eric, Lafrance, Marie‐Josée
Format: Article
Language:English
Subjects:
Antiviral Agents
Antiviral Agents - adverse effects
Carcinoma, Hepatocellular
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - epidemiology
Chronic infection
Cirrhosis
Guanine
Guanine - analogs & derivatives
Hepatitis B
Hepatitis B virus
Hepatitis B, Chronic
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - epidemiology
Hepatocellular carcinoma
Humans
Infections
Life Sciences
Liver cirrhosis
Liver Neoplasms
Liver Neoplasms - drug therapy
Liver Neoplasms - epidemiology
Liver transplantation
Prospective Studies
Santé publique et épidémiologie
Tenofovir
Tenofovir - adverse effects
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications. Aim To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort. Methods All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co‐infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW). Results The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow‐up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir‐ (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person‐years) and entecavir‐treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person‐years, respectively. Conclusion The risk of liver‐related events or death was not different between tenofovir‐ and entecavir‐treated patients in this large prospective cohort of predominantly non‐cirrhotic French patients. Trial registration number: NCT019553458.
ISSN:0269-2813
0953-0673
1365-2036
DOI:10.1111/apt.16197